Annals of Oncology

Journal

Publication Venue For

  • Distinct genomic landscapes of gastroesophageal adenocarcinoma depending on PD-L1 expression identify mutations in RAS–MAPK pathway and TP53 as potential predictors of immunotherapy efficacy.  32:906-916. 2021
  • Disparities in clinical outcomes across age, sex and race among patients with pancreatic adenocarcinoma: a single center experience.  30:iv64. 2019
  • Efficacy and tolerability of the combination of Liposomal irinotecan and 5-fluorouracil/leucovorin in advanced pancreatic cancers: post-approval clinic experience.  30:iv74. 2019
  • Neoadjuvant modified FOLFIRINOX or gemcitabine-nab paclitaxel followed by stereotactic body radiotherapy for patients with locally advanced pancreatic cancer.  30:iv67. 2019
  • Outcomes of Gastrointestinal cancers treated on Phase 1 clinical trials at O'Neal Comprehensive Cancer Center.  30:iv66. 2019
  • Ramucirumab plus merestinib in previously treated metastatic colorectal cancer: safety, pharmacokinetic, and preliminary efficacy findings from a Phase 1 study.  30:iv124. 2019
  • Stereotactic body radiotherapy in locally advanced pancreatic adenocarcinoma: A single institution experience.  30:iv89. 2019
  • Bevacizumab-induced radiosenitzation in small cell lung cancer.  29:ix148. 2018
  • First report of real-world patient characteristics and treatment patterns from POLARIS: Palbociclib in hormone receptor-positive (HR+) advanced breast cancer: A prospective, multicenter, noninterventional study.  29:viii112-viii113. 2018
  • Germline and somatic DNA damage repair gene mutations and overall survival in metastatic pancreatic ductal adenocarcinoma patients treated with FOLFIRINOX.  29:viii242. 2018
  • Phase Ib/II, open label, multicenter study of intratumoral SD-101 in combination with pembrolizumab in anti-PD-1 treatment naïve patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).  29:viii375. 2018
  • Results of phase II trial of SL-701, a novel immunotherapy targeting IL-13Ra2, EphA2, and survivin, in adults with second-line recurrent glioblastoma (GBM).  29:viii122-viii123. 2018
  • Adjuvant everolimus in high-risk diffuse large B-cell lymphoma: Final results from the PILLAR-2 randomized phase III trial.  29:707-714. 2018
  • Multi-institutional competing risks analysis of distant brain failure and salvage patterns after upfront radiosurgery without whole brain radiotherapy for brain metastasis.  29:497-503. 2018
  • Non-coding MIR491 is associated with less EGFr expression and greater radiosensitivity in human head and neck cancer cell lines.  28:x6. 2017
  • Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide.  28:2264-2271. 2017
  • Efficacy of a novel antibody-drug conjugate (ADC), ABT-414, with temozolomide (TMZ) in recurrent glioblastoma (rGBM).  27:vi103. 2016
  • Hyponatremia and hypoalbuminemia as predictive factors for response to first line treatment for metastatic non-small cell lung cancer.  27:vi36. 2016
  • Long-term outcomes after adjuvant treatment of sequential versus combination docetaxel with doxorubicin and cyclophosphamide in node-positive breast cancer: BCIRG-005 randomized trial.  27:1041-1047. 2016
  • Phase I dose-escalating trial of Escherichia coli purine nucleoside phosphorylase and fludarabine gene therapy for advanced solid tumors.  26:1481-1487. 2015
  • Screening for the Prevalence of EGFR and Alk Mutations in Lung Adenocarcinoma Patients in the Levant Area, a Prospective Analysis.  26:i1-i1. 2015
  • Induction cetuximab, paclitaxel, and carboplatin followed by chemoradiation with cetuximab, paclitaxel, and carboplatin for stage III/IV head and neck squamous cancer: a phase II ECOG-ACRIN trial (E2303).  25:2036-2041. 2014
  • A phase I dose escalation study of oral c-MET inhibitor tivantinib (ARQ 197) in combination with gemcitabine in patients with solid tumors.  25:1416-1421. 2014
  • Acute leukemia and myelodysplasia after adjuvant chemotherapy for breast cancer: Durable remissions after hematopoietic stem cell transplantation.  20:2000-2006. 2009
  • Race and ethnicity correlate with survival in patients with gastric adenocarcinoma.  21:152-160. 2009
  • Phase II trial of docetaxel-irinotecan combination in advanced esophageal cancer.  20:1242-1248. 2009
  • A randomized, phase II trial of two dose schedules of carboplatin/ paclitaxel/cetuximab in stage IIIB/IV non-small-cell lung cancer (NSCLC).  20:1068-1073. 2009
  • Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): A meta-analysis of individual data from 1764 patients.  17:473-483. 2006
  • Randomized phase III trial comparing cisplatin-etoposide to carboplatin-paclitaxel in advanced or metastatic non-small cell lung cancer.  16:1069-1075. 2005
  • An endogastric capsule for measuring tumor markers in gastric juice: An evaluation of the safety and efficacy of a new diagnostic tool.  14:105-109. 2003
  • Clearing of cells bearing the bcl-2 [t(14;18)] translocation from blood and marrow of patients treated with rituximab alone or in combination with CHOP chemotherapy.  12:109-114. 2001

    • International Standard Serial Number (issn)

  • 0923-7534

    • Electronic International Standard Serial Number (eissn)

  • 1569-8041